Jazz Pharmaceuticals (JAZZ) Proxy filing summary

Executive summary

• The proxy statement outlines proposals for the 2026 Annual General Meeting, including director elections, auditor ratification, executive compensation, and share issuance authorities.

• The company reported $4.3B in total revenues and $1.4B in net cash from operating activities for 2025, serving ~100 countries with 2,800 employees and 9 marketed medicines.

• Key 2025 achievements include record financial performance, multiple regulatory approvals, and significant pipeline progress, notably in rare diseases and oncology.

• Forward-looking statements emphasize growth through commercial launches, R&D, and strategic capital deployment.

Voting matters and shareholder proposals

• Shareholders will vote on electing three directors, ratifying KPMG as auditors, approving executive compensation, granting board authority to issue shares, and related proposals.

• Board recommends voting FOR all proposals, including renewal of share issuance authority and opt-out of pre-emption rights for up to 20% of issued share capital.

• Adjournment proposal allows for additional proxy solicitation if needed for share issuance proposals.

Board of directors and corporate governance

• Board consists of 13 members with diverse skills, experience, and backgrounds; 11 are independent.

• Recent board refreshment added four new directors since 2024; ongoing evaluation and self-assessment processes are in place.

• Board committees include Audit, Compensation, Nominating, and Science & Medicine, all with independent members.

• Share ownership guidelines, anti-hedging/pledging, and clawback policies are enforced.